[Form 3] Design Therapeutics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Design Therapeutics, Inc. reported an initial Form 3 for director Justin D. Gover relating to an event on 09/09/2025. The filing states the reporting person is a Director and that no securities are beneficially owned by Mr. Gover as of the reporting date. The Form 3 was signed by an attorney-in-fact on 09/10/2025. The filing notifies investors that the director currently holds no direct or indirect equity in the issuer.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gover Justin D.

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CA 92011

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/09/2025

3. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Mustapha Parekh, Attorney-in-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 for Design Therapeutics (DSGN) disclose?

The Form 3 discloses that director Justin D. Gover filed an initial statement for the event dated 09/09/2025 and that no securities are beneficially owned by him.

Does Justin D. Gover own any shares of DSGN according to the filing?

No. The filing explicitly states no securities are beneficially owned by the reporting person.

What is the reporting person's relationship to Design Therapeutics (DSGN)?

The filing lists the reporting person as a Director of Design Therapeutics, Inc.

When was the Form 3 signed and by whom?

The signature block shows the form was signed by Mustapha Parekh, Attorney-in-Fact on 09/10/2025.

Was this Form 3 filed jointly or by one reporting person?

The filing indicates it was a Form filed by One Reporting Person.